Riskpilot← Back to searchSign inGet full accessISQ Pharma AB
ABActiveOrg 5568020621Åkergatan 16Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20100 employees
Revenue 2024
SEK 0
EBITDA margin
—
+53% vs 2023
Equity ratio
86.1%
Financial strength
Net profit 2024
SEK 621K
+4% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -22K | +53% |
| Net profit | SEK 621K | +4% |
| Total assets | SEK 1,7M | +12% |
| Equity | SEK 1,5M | -1% |
| Employees | 0 | — |
Legal name
ISQ Pharma AB
Org number
5568020621
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
10 mars 2010
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget har till föremål för sin verksamhet att förvalta aktier i bolag som bedriver apoteksverksamhet samt tillverka , handla med och tillhandahålla vårdnära samt friskvårds produkter.
Address
Åkergatan 16
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −17 | −18 | −19 | −48 | −22 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | −17 | −18 | −19 | −48 | −22 |
| Net financials | 690 | 838 | −1 | 644 | 644 |
| Profit before tax | 673 | 820 | — | — | — |
| Tax | −0 | −0 | — | — | — |
| Net profit | 673 | 820 | −20 | 596 | 621 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 100 | 1 979 | 1 305 | 1 518 | 1 698 |
| Equity | 1 366 | 1 503 | 889 | 1 484 | 1 462 |
| Long-term debt | 568 | 0 | — | — | — |
| Short-term debt | 165 | 477 | 417 | 34 | 235 |
| Total debt | 733 | 477 | 417 | 34 | 235 |
EBITDA margin
-2230600.0%
This company
15.8%
Market median
-14117822% vs market
20202024
Equity ratio
86.1%
This company
38.2%
Market median
+125% vs market
20202024
Return on equity
42.5%
This company
18.4%
Market median
+131% vs market
20202024
Net profit margin
62132900.0%
This company
8.1%
Market median
+767072740% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.16×
This company
0.62×
Market median
+74% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
ME Chief Auditor | Chief Auditor | 2022 |
NH Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Chairman | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ISQ Pharma AB 
Apoteksgruppen i Göteborg Nr 3 ABBoard members of ISQ Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Malin Elisabeth Terneblad | Chief Auditor | 0 companies |
| Navid Hossein Moattar | Deputy Chief Executive Officer | 0 companies |
| Elena Alejandra Diaz Cifuentes | Deputy Board Member | 0 companies |
| Masoud Ghavidel Fahraj | Chairman | 0 companies |